FiercePharma  Mar 19  Comment 
Novo Nordisk’s closely watched semaglutide has already shown it can spur weight loss in diabetic patients. Now it’s added evidence that it can help nondiabetic obesity patients shed pounds, too.
Financial Times  Feb 28  Comment 
Portuguese authorities are investigating 2015 debt sale to US asset manager
Financial Times  Feb 28  Comment 
Repair Impact Fund will help start-ups develop treatment aimed at drug-resistant bacteria
FiercePharma  Feb 23  Comment 
Novo Nordisk has secured 2018 formulary coverage for Ozempic from leading U.S. pharmacy benefit manager Express Scripts, an important step in the early stages of the drug's launch.
FiercePharma  Feb 22  Comment 
Highly anticipated phase 3 results for Novo Nordisk’s oral GLP-1 diabetes therapy, semaglutide, are here, and investors of Novo rival Eli Lilly are taking note. 

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki